vTv Therapeutics Inc. Class A Common Stock (VTVT) is a publicly traded Healthcare sector company. As of October 24, 2026, VTVT trades at $25.73 with a market cap of $107.39M and a P/E ratio of 0.00. VTVT moved -2.41% today. Year to date, VTVT is -39.71%; over the trailing twelve months it is +22.90%. Its 52-week range spans $14.00 to $44.00. Analyst consensus is strong buy with an average price target of $56.80. Rallies surfaces VTVT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
vTv Therapeutics study finds 54% of T1D adults on automated insulin delivery report hypoglycemia-related burdens: A vTv Therapeutics study found that 54% of adults with type 1 diabetes using automated insulin delivery reported burdens related to hypoglycemia.
| Metric | Value |
|---|---|
| Price | $25.73 |
| Market Cap | $107.39M |
| P/E Ratio | 0.00 |
| EPS | $0.00 |
| Dividend Yield | 0.00% |
| 52-Week High | $44.00 |
| 52-Week Low | $14.00 |
| Volume | 867 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-31.08M |
| Gross Margin | 0.00% |
5 analysts cover VTVT: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $56.80.